25,296 Results

Bortezomib Accord

Bortezomib Accord
(Bortezomib)
Type
Medicinal product subject to restricted medical prescription
ATC

Ibandronic Acid Teva

Ibandronic Acid Teva
(Ibandronic Acid)
Type
50 mg: Medicinal product subject to restricted medical prescription / 150 mg: Medicinal product subject to medical prescription
ATC

Memantine ratiopharm

Memantine ratiopharm
(Memantine)
Type
Medicinal product subject to restricted medical prescription
ATC

Cognitive Function in a Randomized Trial of Evolocumab.

Background: Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol...

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Objective: To evaluate the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background therapy.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Background: The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma.

APOLLO phase III study of ALN TTR02 (patisiran) in hereditary ATTR amyloidosis with polyneuropathy meets primary endpoints.- Sanofi Genzyme + Alnylam Pharmaceuticals.

 Added 1 day ago

Sanofi Genzyme and Alnylam Pharmaceuticals announced that the APOLLO Phase III study of ALN TTR02 (patisiran), for patients with hereditary...

Phase III study of Intuniv (guanfacine hydrochloride prolonged release) meets primary endpoint in adults with attention deficit hyperactivity disorder.- Shire + Shionogi.

 Added 1 day ago

Shire and Shionogi announced that a Phase III study evaluating Intuniv (guanfacine hydrochloride prolonged release) in adult patients with attention...

Phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) meets primary endpoint in chronic obstructive pulmonary disease.- GlaxoSmithKline + Innoviva.

 Added 1 day ago

GlaxoSmithKline and Innoviva announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI)...

FDA Oncologic Drug Advisory Committee voted 6 in favor and 6 against the benefit-risk profile for Sutent (sunitinib) in patients at high risk of recurrent renal cell carcinoma after surgery.- Pfizer.

 Added 1 day ago

Pfizer Inc. has announced that the FDA Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the...

Load more